Latigo Raises $150m To Drive Its First Pain Drug Toward Phase III

Series B Proceeds Will Fund Three NaV1.8 Candidates

Vertex has the first-in-class NaV1.8 inhibitor for acute pain, Journavx, but Latigo plans to bring forward multiple best-in-class options for acute and chronic pain against NaV1.8 and other targets.

Latigo has three NaV1.8 inhibitors and an ASIC inhibitor in development (Shutterstock)

More from Financing

More from Scrip